Scopus BioPharma completes clinical lot manufacturing

Scopus BioPharma announced the completion of clinical lot manufacturing fulfilling the requirements for the planned Phase 1 clinical trial for non-Hodgkin's lymphoma. This is a key milestone to enable finalization of the investigational new drug, or IND, package for submission to the FDA. Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, "The clinical lot completion is a very important step. In connection with our recent IPO, we informed investors that this would be a near-term value-building milestone. This is the first of several important milestones anticipated for H1 2021. We look forward to providing further updates to shareholders on near-term clinical and operational milestones in the weeks and months ahead."